Security
Protara Therapeutics, Inc. Common Stock · TARA
TARANASDAQCommon stockCurrentCIK 1359931Updated Oct 6, 2026
Name history
Protara Therapeutics, Inc. · through Aug 13, 2026ArTara Therapeutics, Inc. · through Apr 23, 2020PROTEON THERAPEUTICS INC · through Dec 31, 2019
TARA price & chart
Loading TradingView…
NASDAQ:TARA on TradingView ↗About the company
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in ongoing clinical trials in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
In the news
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting ↗
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 144,636,000Source | 94,090,000Source | 176,093,000Source | 156,933,000Source | 101,647,000Source | 191,923,000Source | 168,559,000Source | 68,134,000Source | 209,468,000Source | 181,454,000Source | 78,954,000Source | 113,290,000Source |
| Property, Plant and Equipment, NetUSD | 828,000Source | 1,109,000Source | 1,318,000Source | 912,000Source | 1,185,000Source | 669,000Source | 988,000Source | 1,213,000Source | 759,000Source | 1,027,000Source | 1,296,000Source | 1,592,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,551,000Source | 51,757,000Source | 17,076,000Source | 31,496,000Source | 89,581,000Source | 14,737,000Source | 91,461,000Source | 52,231,000Source | 49,657,000Source | 162,798,000Source | 39,586,000Source | 24,127,000Source |
| Assets, CurrentUSD | 135,644,000Source | 85,082,000Source | 146,152,000Source | 125,091,000Source | 92,214,000Source | 139,997,000Source | 126,532,000Source | 57,913,000Source | 159,504,000Source | 172,155,000Source | 68,705,000Source | 86,146,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,974,000Source | 3,583,000Source | 3,658,000Source | 2,875,000Source | 2,633,000Source | 4,211,000Source | 2,169,000Source | 2,690,000Source | 3,950,000Source | 1,863,000Source | 3,125,000Source | 1,776,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,452,000Source | 4,514,000Source | 2,602,000Source | 3,725,000Source | 4,768,000Source | 2,891,000Source | 3,992,000Source | 5,018,000Source | 3,174,000Source | 4,255,000Source | 5,264,000Source | 6,277,000Source |
| Other Assets, NoncurrentUSD | 21,000Source | 33,000Source | 74,000Source | 29,000Source | 19,000Source | 76,000Source | 35,000Source | 31,000Source | 20,000Source | 27,000Source | 11,000Source | 644,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 12,345,000Source | 12,299,000Source | 14,782,000Source | 12,510,000Source | 9,597,000Source | 10,715,000Source | 10,075,000Source | 9,728,000Source | 13,056,000Source | 14,320,000Source | 10,633,000Source | 11,207,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 39,000Source | 21,000Source | 59,000Source | 39,000Source | 21,000Source | 55,000Source | 39,000Source | 11,000Source | 54,000Source | 35,000Source | 11,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 417,221,000Source | 313,952,000Source | 503,484,000Source | 416,161,000Source | 313,021,000Source | 501,718,000Source | 415,250,000Source | 269,875,000Source | 498,687,000Source | 412,077,000Source | 268,725,000Source | 262,724,000Source |
| Retained Earnings (Accumulated Deficit)USD | -285,112,000Source | -232,211,000Source | -341,869,000Source | -271,854,000Source | -220,992,000Source | -320,201,000Source | -256,894,000Source | -211,479,000Source | -302,419,000Source | -244,980,000Source | -200,384,000Source | -159,964,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 143,000Source | 29,000Source | -363,000Source | 77,000Source | — | -364,000Source | 89,000Source | -1,000Source | 90,000Source | 2,000Source | -31,000Source | -688,000Source |
| Stockholders' Equity Attributable to ParentUSD | 132,291,000Source | 81,791,000Source | 161,311,000Source | 144,423,000Source | 92,050,000Source | 181,208,000Source | 158,484,000Source | 58,406,000Source | 196,412,000Source | 167,134,000Source | 68,321,000Source | 102,083,000Source |
| Liabilities and EquityUSD | 144,636,000Source | 94,090,000Source | 176,093,000Source | 156,933,000Source | 101,647,000Source | 191,923,000Source | 168,559,000Source | 68,134,000Source | 209,468,000Source | 181,454,000Source | 78,954,000Source | 113,290,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,909,000Source | 8,642,000Source | 13,319,000Source | 9,761,000Source | 5,648,000Source | 8,922,000Source | 7,018,000Source | 5,501,000Source | 10,939,000Source | 10,961,000Source | 6,149,000Source | 5,740,000Source |
| Operating Lease, Liability, CurrentUSD | 1,220,000Source | 1,079,000Source | 1,286,000Source | 1,199,000Source | 1,035,000Source | 1,264,000Source | 1,170,000Source | 1,000,000Source | 1,242,000Source | 1,124,000Source | 983,000Source | 917,000Source |
| Accounts Payable, CurrentUSD | 4,504,000Source | 2,295,000Source | 4,663,000Source | 5,299,000Source | 1,385,000Source | 4,031,000Source | 2,310,000Source | 972,000Source | 3,468,000Source | 4,429,000Source | 2,434,000Source | 1,586,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,436,000Source | 3,657,000Source | 1,463,000Source | 2,749,000Source | 3,949,000Source | 1,793,000Source | 3,057,000Source | 4,227,000Source | 2,117,000Source | 3,359,000Source | 4,484,000Source | 5,467,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,185,000Source | 5,268,000Source | 7,370,000Source | 3,263,000Source | 3,228,000Source | 3,627,000Source | 3,538,000Source | 3,529,000Source | 6,229,000Source | 5,408,000Source | 2,732,000Source | 3,237,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 1,047,000Source | 931,000Source | 1,384,000Source | 903,000Source | 1,362,000Source | 833,000Source | 3,826,000Source | 4,125,000Source | 6,092,000Source | 6,688,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,089,000Source | -1,504,000Source | -873,000Source | 1,381,000Source | 848,000Source | 631,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -11,041,000Source | -19,775,000Source | -13,751,000Source | -9,022,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -21,343,000Source | -14,713,000Source | -56,365,000Source | -35,808,000Source | -37,557,000Source | -26,457,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -14,721,000Source | -58,354,000Source | -139,491,000Source | 19,155,000Source | 53,107,000Source | 14,950,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 44,000Source | 94,000Source | 63,000Source | 45,000Source | 120,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 91,000Source | 90,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,144,000Source | 1,730,000Source | 82,715,000Source | 139,865,000Source | -91,000Source | -90,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 13,296,000Source | 52,502,000Source | 17,821,000Source | 32,241,000Source | 15,482,000Source | 92,206,000Source | 50,402,000Source | 163,543,000Source | 40,331,000Source | 24,872,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 931,000Source | — | — | — | — | — | — | 6,092,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 90,000Source | 83,000Source | 362,000Source | 332,000Source | 341,000Source | 248,000Source |
| General and Administrative ExpenseUSD | — | — | 5,169,000Source | 4,260,000Source | 6,369,000Source | 5,816,000Source | 6,067,000Source | 4,976,000Source | 21,916,000Source | 17,450,000Source | 18,624,000Source | 20,737,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 29,517,000Source |
| Investment Income, InterestUSD | — | — | 1,502,000Source | 1,111,000Source | 1,656,000Source | 1,626,000Source | 1,847,000Source | 1,729,000Source | 6,380,000Source | 4,171,000Source | 3,193,000Source | 1,110,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -13,258,000Source | -11,219,000Source | -21,668,000Source | -14,960,000Source | -17,782,000Source | -11,914,000Source | -57,439,000Source | -44,596,000Source | -40,420,000Source | -65,952,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -40,420,000Source | 65,952,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,502,000Source | 1,111,000Source | 1,656,000Source | 1,626,000Source | 1,847,000Source | 2,210,000Source | 7,110,000Source | 4,558,000Source | 3,193,000Source | 1,110,000Source |
| Operating ExpensesUSD | — | — | 14,760,000Source | 12,330,000Source | 23,324,000Source | 16,586,000Source | 19,629,000Source | 14,124,000Source | 64,549,000Source | 49,154,000Source | 43,613,000Source | 67,062,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 21,000Source | 135,000Source | — | — |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | 9,000Source | — | 0Source | 17,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -14,760,000Source | -12,330,000Source | -23,324,000Source | -16,586,000Source | -19,629,000Source | -14,124,000Source | -64,549,000Source | -49,154,000Source | -43,613,000Source | -67,062,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 57,351,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -13,258,000Source | -11,219,000Source | -21,668,000Source | -14,960,000Source | -17,782,000Source | -11,914,000Source | -57,439,000Source | -44,596,000Source | -40,420,000Source | -65,952,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.31Source | -0.5Source | -0.36Source | -0.35Source | -0.31Source | -0.29Source | -1.34Source | -2.17Source | -3.57Source | -5.86Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.31Source | -0.5Source | -0.36Source | -0.35Source | -0.31Source | -0.29Source | -1.34Source | -2.17Source | -3.57Source | -5.86Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 42,272,104Source | 22,329,772Source | 61,006,766Source | 42,270,855Source | 57,538,833Source | 40,707,937Source | 42,836,129Source | 20,592,847Source | 11,331,338Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 42,272,104Source | 22,329,772Source | 61,006,766Source | 42,270,855Source | 57,538,833Source | 40,707,937Source | 42,836,129Source | 20,592,847Source | 11,331,338Source | 11,259,615Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 5,169,000Source | 4,260,000Source | 6,369,000Source | 5,816,000Source | 6,067,000Source | 4,976,000Source | 21,916,000Source | 17,450,000Source | 18,624,000Source | 20,737,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 29,517,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 57,309,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | — | -5.86Source |
| Interest and Other IncomeUSD | — | — | 1,058,000Source | 659,000Source | — | 1,223,000Source | 1,656,000Source | 1,555,000Source | 5,023,000Source | 3,326,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | 659,000Source | — | — | — | — | — | — | 2,727,000Source | 2,230,000Source |
| Investment Income, InterestUSD | — | — | 1,502,000Source | 1,111,000Source | 1,656,000Source | 1,626,000Source | 1,847,000Source | 1,729,000Source | 6,380,000Source | 4,171,000Source | 3,193,000Source | 1,110,000Source |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 1,110,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -40,420,000Source | 65,952,000Source |
| Net Investment IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 17,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,502,000Source | 1,111,000Source | 1,656,000Source | 1,626,000Source | 1,847,000Source | 2,210,000Source | 7,110,000Source | 4,558,000Source | 3,193,000Source | 1,110,000Source |
| Operating ExpensesUSD | — | — | 14,760,000Source | 12,330,000Source | 23,324,000Source | 16,586,000Source | 19,629,000Source | 14,124,000Source | 64,549,000Source | 49,154,000Source | 43,613,000Source | 67,062,000Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 3,237,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | 9,000Source | — | 0Source | 17,000Source |
| Research and Development ExpenseUSD | — | — | 9,591,000Source | 8,070,000Source | 16,955,000Source | 10,770,000Source | 13,562,000Source | 9,148,000Source | 42,633,000Source | 31,704,000Source | 24,989,000Source | 16,808,000Source |
| Interest Income (Expense), Net | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-295862
Filing attachments
ea029923601ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ea029923601ex99-1.htm PRESS RELEASE DATED AUGUST 11, 2026, ISSUED BY THE REGISTRANT Exhibit 99.1 Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients a…
Read attachment ↗ea028858101ex99-1.htm · 8-K · 2026-05-13
EX-99.1 2 ea028858101ex99-1.htm PRESS RELEASE DATED MAY 13, 2026, ISSUED BY THE REGISTRANT Exhibit 99.1 Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) perspectives on May 19, 2026 at 4:30 pm ET Interim safety and durability data …
Read attachment ↗ea028040401ex99-1.htm · 8-K · 2026-03-10
EX-99.1 2 ea028040401ex99-1.htm PRESS RELEASE DATED MARCH 10, 2026, ISSUED BY THE REGISTRANT Exhibit 99.1 Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of th…
Read attachment ↗ea027797201ex99-1_protara.htm · 8-K · 2026-02-24
EX-99.1 2 ea027797201ex99-1_protara.htm PRESS RELEASE, DATED FEBRUARY 23, 2026 Exhibit 99.1 TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW Y…
Read attachment ↗ea027797201ex99-2_protara.htm · 8-K · 2026-02-24
EX-99.2 3 ea027797201ex99-2_protara.htm INVESTOR PRESENTATION, DATED FEBRUARY 24, 2026 Exhibit 99.2 Interim Data Presentation from the ADVANCED - 2 Trial of TARA - 002 in Patients with NMIBC American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium February 2026 2 Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protar…
Read attachment ↗ea026824801ex99-1_protara.htm · 8-K · 2025-12-03
EX-99.1 2 ea026824801ex99-1_protara.htm INVESTOR PRESENTATION, DATED DECEMBER 3, 2025 Exhibit 99.1 Interim Data Presentation From the ADVANCED - 2 Trial of TARA - 002 in BCG - Naïve NMIBC Patients Society Of Urologic Oncology Annual Meeting December 2025 2 Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" wi thi n the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use term…
Read attachment ↗